Abstract 910
Background
Liver cancer is the fifth commonest cancer. As per the World Health Organization liver disease is the tenth most common cause of death in India. Among all liver cancers, Hepatocellular carcinoma (HCC) is the most frequent cause and comprises 90% of liver cancer. Liver cancer is one of the leading causes of death worldwide due to its aggressive nature and poor survival rate. Due to the advancement of new technologies, the demand of high quality of biological samples has increased for translational research and drug discovery. Biobank are a suitable place to get a high quality of annotated biosamples. Biobank are playing important role in the field of cancer research, diagnosis, prognosis, and treatment. Most of the Biobank are situated in economically developed countries while cancer and other related disease are more in developing countries. The Indian government has established a world-class National Liver Disease Biobank in 2017 with a capacity of 5.4 million samples. Its aim is to accelerate research and personalized treatment in India.
Methods
The Biobank has collaboration with different hospitals from all over India. It is following Decentralized collection, centralized storage, and informatics. All centers are collecting biosamples as per SOPs of National Liver Disease Biobank.
Results
The Biobank collects, process and store a wide array of biospecimens (tumor tissue, adjacent normal tissue, blood, plasma, serum, buffycoat……) using validated SOPs. At present Our Biobank has collaboration with three hospitals and four research centers. It has collected 2566 biosamples and has involved in many research projects.
Conclusions
Establishment of the biobank is a major step in liver cancer related clinical and basic research in India The aim of NLDB Biobank is to accelerate HCV, liver disease, and associated cancer research. It is a first and biggest Liver Biobank in India, have a network from different hospitals across the country. We have been involving in many research projects which results would be highly useful in patient care and cancer research, biomarker discovery and translational research.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National Liver Disease Biobank.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1310 - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality approach in a 10-year single institution study
Presenter: Ajung Chu
Session: Poster display - Cocktail
Resources:
Abstract
489 - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer.
Presenter: Yumei Shi
Session: Poster display - Cocktail
Resources:
Abstract
838 - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105 trial: NCT02685111)
Presenter: Jaeho Jeong
Session: Poster display - Cocktail
Resources:
Abstract
1337 - Painful scalp during chemotherapy induced hair loss is associated to permanent alopecia in breast cancer patients
Presenter: Nesrine Mejri
Session: Poster display - Cocktail
Resources:
Abstract
1445 - Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran
Presenter: Shima Pashaei
Session: Poster display - Cocktail
Resources:
Abstract
1457 - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant chemotherapy for breast cancer?
Presenter: Ayako Ueno
Session: Poster display - Cocktail
Resources:
Abstract
759 - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and Circulating Interluekin-6 (IL-6) as biomarker in Breast Cancer Patients
Presenter: Md Shah Jalalur Rahman Shahi
Session: Poster display - Cocktail
Resources:
Abstract
1447 - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients
Presenter: Helenia Putri
Session: Poster display - Cocktail
Resources:
Abstract
1175 - Association of Serum Vitamin D Level and Vitamin D Receptor Polymorphism (Apa 1) And Breast Cancer
Presenter: Suzy Gohar
Session: Poster display - Cocktail
Resources:
Abstract
911 - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival in Breast Cancer Patients Not Achieving Pathological Complete Response After Neoadjuvant Chemotherapy
Presenter: Jianguo Lai
Session: Poster display - Cocktail
Resources:
Abstract